Lakefront Biotherapeutics NV (LKFT) Stock

Lakefront Biotherapeutics NV (LKFT) is a Healthcare stock trading at $28.80 (as of 2026-08-21), with a market capitalization of $1.93B and a trailing P/E of 6.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Understand Lakefront Biotherapeutics NV: how it makes money

Lakefront Biotherapeutics NV is a Healthcare company in Pharmaceutical Products, generating revenue from its biotherapeutics or pharmaceutical products business.

With an operating margin of -33%, the profit model is currently loss-making, so future value depends on turning revenue growth into sustainable operating profitability.

Business quality (Mixed): Business quality grade is Mixed, while valuation looks Cheap (P/E 6.2× vs Pharmaceutical Products industry 17×).

Valuation: At 6× earnings, LKFT trades 63% below the Pharmaceutical Products average (17×). Note: the low multiple may reflect one-time earnings items.

Bull case

  • Strong recent top-line momentum: The company reported quarterly revenue $0.1B (+35% YoY). If this growth persists, it gives more scale that can potentially support better operating leverage over time.
  • Valuation discounts the stock: P/E 6.2× vs Pharmaceutical Products industry 17× (63% below) suggests the market is valuing the business well under the industry multiple. That can create upside if profitability improves faster than investors expect.

Bear case

  • Deep operating losses persist: The operating margin is -33%. This indicates ongoing cost pressure that can limit cash generation and increase the risk of dilution or restructuring needs if conditions worsen.
Valuation — source: SEC EDGAR (first-party)
Price$28.80
Market Cap$1.93B
P/E Ratio6.0
Price / Book0.60
Price / Sales1.74
DCF Value (model)$44.64
DCF Upside vs Price55.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.11B
Net Margin28.9%
Return on Equity9.9%
Current Ratio20.15
Revenue Growth (YoY)303.5%
EPS Growth (YoY)334.8%
Valuation vs Sector & Industry
Stock P/E6.0
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
vs Sector-72.3%
vs Industry-64.9%
Company
SectorHealthcare
IndustryPharmaceutical Products

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Prestige Consumer Healthcare Inc. (PBH)
  • ACADIA Pharmaceuticals Inc. (ACAD)
  • Indivior Pharmaceuticals Inc (INDV)
  • Phibro Animal Health Corporation (PAHC)
  • Ionis Pharmaceuticals, Inc. (IONS)
  • Harmony Biosciences Holdings, Inc. (HRMY)
  • Arrowhead Pharmaceuticals, Inc. (ARWR)
  • Corcept Therapeutics Incorporated (CORT)
LKFT earnings history · LKFT institutional & insider holders · LKFT KPIs & operating metrics · LKFT financials · LKFT investor presentations & press releases · LKFT SEC filings · LKFT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.